RetinAI Discovery manages and analyses ophthalmic imaging: OCT scans and fundus images collected from multiple device formats, with automatic AI segmentation on top. OCT Atlas is CE-marked for age-related macular degeneration, diabetic retinopathy, macular oedema and glaucoma, and LuxIA gained CE-MDR certification for diabetic retinopathy screening in April 2025.
Retinal imaging is a strong fit for automated analysis because the measurements that matter, layer thickness and fluid volume, are quantitative, tedious and variable when done by eye. Regulatory marking is what separates a clinical product from a research demo here, and this one has it.
Ikerian AG in Bern ships Discovery UNITY for unified data, editions for clinical studies and for clinics, and CONNECT for collaboration, and raised a Series B in October 2024. No pricing is published, CE marking is not FDA clearance so availability differs by market, and analysis supports an ophthalmologist’s decision rather than replacing it.
